SG11201508330WA - Anti-angiogenesis compound, intermediate and use thereof - Google Patents
Anti-angiogenesis compound, intermediate and use thereofInfo
- Publication number
- SG11201508330WA SG11201508330WA SG11201508330WA SG11201508330WA SG11201508330WA SG 11201508330W A SG11201508330W A SG 11201508330WA SG 11201508330W A SG11201508330W A SG 11201508330WA SG 11201508330W A SG11201508330W A SG 11201508330WA SG 11201508330W A SG11201508330W A SG 11201508330WA
- Authority
- SG
- Singapore
- Prior art keywords
- angiogenesis compound
- angiogenesis
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310122138 | 2013-04-09 | ||
| PCT/CN2014/074977 WO2014166386A1 (en) | 2013-04-09 | 2014-04-09 | Anti-angiogenesis compound, intermediate and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201508330WA true SG11201508330WA (en) | 2015-11-27 |
Family
ID=51688942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201508330WA SG11201508330WA (en) | 2013-04-09 | 2014-04-09 | Anti-angiogenesis compound, intermediate and use thereof |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9540381B2 (en) |
| EP (1) | EP2985283B1 (en) |
| JP (1) | JP6152921B2 (en) |
| KR (1) | KR101854203B1 (en) |
| CN (2) | CN104334543B (en) |
| AU (1) | AU2014252584B2 (en) |
| CA (1) | CA2908849C (en) |
| ES (1) | ES2899726T3 (en) |
| HK (1) | HK1215566A1 (en) |
| NZ (1) | NZ713187A (en) |
| SG (1) | SG11201508330WA (en) |
| WO (1) | WO2014166386A1 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2985283B1 (en) | 2013-04-09 | 2021-10-06 | Guangzhou Kangrui Biological Pharmaceutical Technology Co., Ltd. | Anti-angiogenesis compound, intermediate and use thereof |
| US11352353B2 (en) * | 2016-05-27 | 2022-06-07 | Hangzhou Innogate Pharma Co., Ltd. | Heterocyclic compound serving as FGFR4 inhibitor |
| CN107812006A (en) * | 2017-11-13 | 2018-03-20 | 全椒先奇医药科技有限公司 | One kind treats acute renal failure pharmaceutical composition and its application |
| KR20230008148A (en) | 2020-04-24 | 2023-01-13 | 광저우 캉루이 바이오로지컬 파마슈티컬 테크놀로지 씨오., 엘티디. | Formulations to treat eye conditions |
| CN111743885B (en) * | 2020-08-17 | 2022-03-15 | 山东省科学院生物研究所 | Application of p-hydroxyphenylacetic acid in preventing and/or treating cardiovascular diseases |
| CN112194598B (en) * | 2020-10-15 | 2021-12-21 | 郑州猫眼农业科技有限公司 | Process for the preparation of 3- (tert-butoxycarbonyl-R-oxycarbonylmethyl-amino) -propanoate |
| WO2023143611A1 (en) * | 2022-01-30 | 2023-08-03 | 兰泰克生物技术公司 | Method for treating cancer |
| CN114634421A (en) * | 2022-02-24 | 2022-06-17 | 济宁晟泰药业有限公司 | Preparation method of dasatinib intermediate |
| CN117164580A (en) * | 2022-05-27 | 2023-12-05 | 苏州泽璟生物制药股份有限公司 | Preparation method of KRAS G12C inhibitor and intermediate thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4757743A (en) * | 1987-04-29 | 1988-07-19 | Vickers, Incorporated | Power transmission |
| KR20080015482A (en) | 1999-02-10 | 2008-02-19 | 아스트라제네카 아베 | Quinazoline derivatives as angiogenesis inhibitors |
| BRPI0507373A (en) * | 2004-01-23 | 2007-07-10 | Amgen Inc | compounds and method of use |
| DE102005016634A1 (en) * | 2005-04-12 | 2006-10-19 | Merck Patent Gmbh | Novel aza heterocycles as kinase inhibitors |
| GT200600411A (en) * | 2005-09-13 | 2007-05-21 | Novartis Ag | COMBINATIONS THAT INCLUDE AN INHIBITOR OF THE RECEIVER OF THE VASCULAR ENDOTELIAL GROWTH FACTOR |
| RU2008127486A (en) * | 2005-12-08 | 2010-01-20 | Милленниум Фармасьютикалз, Инк. (Us) | BICYCLIC COMPOUNDS WITH INHIBITOR ACTIVITY AGAINST KINASE |
| GB0604937D0 (en) * | 2006-03-10 | 2006-04-19 | Novartis Ag | Organic compounds |
| GB0605120D0 (en) * | 2006-03-14 | 2006-04-26 | Novartis Ag | Organic Compounds |
| EP2023926B1 (en) * | 2006-05-19 | 2011-10-12 | Bayer Pharma Aktiengesellschaft | Pyridonecarboxamide derivatives useful in treating hyper-proliferative and angiogenesis disorders |
| CN106146473B (en) * | 2013-03-28 | 2020-04-14 | 宁波市方昌医药有限公司 | Anti-angiogenesis compound |
| EP2985283B1 (en) | 2013-04-09 | 2021-10-06 | Guangzhou Kangrui Biological Pharmaceutical Technology Co., Ltd. | Anti-angiogenesis compound, intermediate and use thereof |
-
2014
- 2014-04-09 EP EP14782609.3A patent/EP2985283B1/en active Active
- 2014-04-09 CN CN201480000555.4A patent/CN104334543B/en active Active
- 2014-04-09 ES ES14782609T patent/ES2899726T3/en active Active
- 2014-04-09 CN CN201710702483.3A patent/CN107245071A/en active Pending
- 2014-04-09 KR KR1020157032078A patent/KR101854203B1/en active IP Right Grant
- 2014-04-09 CA CA2908849A patent/CA2908849C/en active Active
- 2014-04-09 JP JP2016506767A patent/JP6152921B2/en active Active
- 2014-04-09 NZ NZ713187A patent/NZ713187A/en unknown
- 2014-04-09 US US14/392,101 patent/US9540381B2/en active Active
- 2014-04-09 AU AU2014252584A patent/AU2014252584B2/en active Active
- 2014-04-09 WO PCT/CN2014/074977 patent/WO2014166386A1/en active Application Filing
- 2014-04-09 SG SG11201508330WA patent/SG11201508330WA/en unknown
-
2016
- 2016-03-21 HK HK16103268.1A patent/HK1215566A1/en unknown
- 2016-10-20 US US15/298,545 patent/US10064864B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10064864B2 (en) | 2018-09-04 |
| KR20150139962A (en) | 2015-12-14 |
| EP2985283A1 (en) | 2016-02-17 |
| US20160075708A1 (en) | 2016-03-17 |
| CN104334543B (en) | 2017-08-25 |
| WO2014166386A1 (en) | 2014-10-16 |
| EP2985283A4 (en) | 2016-09-14 |
| NZ713187A (en) | 2017-04-28 |
| US20170119768A1 (en) | 2017-05-04 |
| CN107245071A (en) | 2017-10-13 |
| HK1215566A1 (en) | 2016-09-02 |
| JP6152921B2 (en) | 2017-06-28 |
| JP2016515636A (en) | 2016-05-30 |
| AU2014252584A1 (en) | 2015-11-05 |
| AU2014252584A8 (en) | 2015-11-12 |
| EP2985283B1 (en) | 2021-10-06 |
| CA2908849A1 (en) | 2014-10-16 |
| US9540381B2 (en) | 2017-01-10 |
| CA2908849C (en) | 2017-11-07 |
| AU2014252584B2 (en) | 2016-10-13 |
| KR101854203B1 (en) | 2018-06-20 |
| CN104334543A (en) | 2015-02-04 |
| ES2899726T3 (en) | 2022-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL274355B (en) | Aza-pyridone compounds and uses thereof | |
| EP2952278A4 (en) | Drill | |
| LT2994467T (en) | Arylquinazolines | |
| SI3038654T1 (en) | New use | |
| HK1215566A1 (en) | Anti-angiogenesis compound, intermediate and use thereof | |
| GB201305825D0 (en) | New use | |
| IL232134A0 (en) | Improved blackbody function | |
| GB201323008D0 (en) | Compounds and uses thereof | |
| HK1207266A1 (en) | Umbrella | |
| GB201307233D0 (en) | Compounds and uses thereof | |
| GB201414328D0 (en) | None | |
| GB201321922D0 (en) | Constructions | |
| ZA201600015B (en) | Anti-fibrogenic compounds, methods and uses thereof | |
| GB201309180D0 (en) | Compounds and Their Uses | |
| GB201314610D0 (en) | Compounds and their uses | |
| GB201306248D0 (en) | Compounds and their uses | |
| GB201410951D0 (en) | None | |
| GB201302180D0 (en) | Umbrella | |
| GB201323005D0 (en) | Compounds and uses thereof | |
| GB201307201D0 (en) | New compounds and uses | |
| GB201307202D0 (en) | New compounds and uses | |
| GB201317353D0 (en) | Ed | |
| GB201318451D0 (en) | W/C Sani-vent | |
| GB201301734D0 (en) | New compounds and uses | |
| GB201309248D0 (en) | Compounds and combinations |